GLP-1RAs: Rethinking treatment intensification in people with T2D - ACRRM

Duration

1 hr

Profession

Physician

# of Credits

1.0

Accreditation

ACRRM

Expiry Date

2020-12-01

It is well established that optimising glycaemic management decreases the risk of microvascular and macrovascular complications. A reduction of 1% glycated haemoglobin (HbA1c) has been associated with reductions in microvascular complications by 37%, myocardial infarction by 14% and death related to diabetes by 21%. Delayed treatment intensification to injectable therapy may be due to a myriad of reasons that may include concerns regarding problematic hypoglycaemia, complex or burdensome regimens, interference with daily living, social stigma and weight gain. Fear of hypoglycaemia was identified as a key barrier to treatment intensification. 75.5% of healthcare professionals reported they would treat more aggressively if it weren’t for the risk of hypoglycaemia with insulin.

This online CME event is an Accredited Distance/Remote based education module as defined by the Professional Development Program of the Australian College of Rural and Remote Medicine. ACRRM member participation and information will be noted and sent directly to the ACRRM for accreditation processing. Please allow 30 days for ACRRM to send you your points. This activity is approved for 1 Core Point(s).

Mark Kennedy
MBBS, BMedSc(Hons), GradDipFamMed
Clinical Associate Professor of General Practice
The University of Melbourne, Melbourne, VIC
Director, Corio Medical Clinical and Coria Diabetic Clinic, Geelong, VIC

Sultan Linjawi
BSc, MBBS, MRCP, FRACP
Director, My Health Explained, Brisbane, QLD
Director and Consultant Physician
(Endocrinology and Diabetes)
Coffs Endocrine and Diabetes Services, Coffs Harbor, NSW

On completion of this program, participants will be better able to:

  1. Review current recommendations for treatment intensification for people with type 2 diabetes (T2D) who require treatment intensification beyond oral agents
  2. Assess when injectable therapy should be considered and appreciate the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in T2D management
  3. Recall the indication, safety and efficacy of GLP-1RAs
  4. Differentiate between GLP-1RA options available in Australia


Related Courses